Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)
Condition: Mammary Cancer Interventions: Drug: Pertuzumab and trastuzumab FDC subcutaneous; Drug: Paclitaxel; Drug: TDM1; Drug: Endocrine therapy; Procedure: Omission surgery Sponsors: David Garcia Cinca; Fundacion Clinic per a la Recerca Biomédica Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Addiction | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Neoadjuvant Therapy | Research